Abstract
The aim: to study features of the cytokine profile in patients with chronic kidney disease receiving treatment by programmed hemodialysis. Materials and methods: the study included 100 patients aged 53,4 ± 15,8 years with chronic kidney disease stage 5D, receiving hemodialysis. All patients were performed a detailed interview to clarify the clinical and anamnestic data, features of pharmacotherapy, physical examination, and complex laboratory research, which included hemogram, biochemical analysis of blood to definition of parameters of kidney function, protein, electrolytes, minerals and iron metabolism, determining the level of interleukin-3 and interleukin-6. Results: anemia was found in 89% of patients, had a normocytic normochromic character with elements of anisocytosis. The most severe anemia was associated with a lower dose of erythropoietin and iron, used in the last month. Interleukin-3 averaged 32,8 ± 8,3 pg / ml, minimum 15 pg / ml, maximum 56 pg / ml, which exceeded reference limits. When comparing the levels of interleukin-3 and erythropoietin dose differing vectors of these parameters in patients with anemia of varying severity were indicated. The correlations between the level of interleukin-3 and the fluctuation of the dose of erythropoietin in the last year (r = 0,54; p = 0,01) in patients with mild anemia, and the level of soluble transferrin receptor (r = 0, 84; p = 0,04) in patients with severe anemia were found. The level of interleukin-6 was also higher than the reference values and amounted to 64,6 ± 8,7 pg / ml, the lowest — 36,0 pg / ml, the most — 86,0 pg / ml. The patients with a high risk of systemic inflammation on the scale of Glasgow Prognostic Score had lower levels of interleukin-6. Conclusions: high levels of interleukin-3 and interleukin-6 were revealed in all patients identified. Inverse relationship of interleukin-3 and dose of erythropoietin in depend of severity of anemia was shown. The high risk of systemic inflammation associated with a lower concentration of interleukin-6, which does not allow its use as a universal marker of inflammation in patients with chronic kidney disease receiving hemodialysis.
Highlights
Согласно современным эпидемиологическим данным распространенность хронической болезни почек (ХБП), в том числе ее терминальной стадии, неуклонно возрастает
Results: anemia was found in 89% of patients, had a normocytic normochromic character with elements of anisocytosis
The most severe anemia was associated with a lower dose of erythropoietin and iron, used in the last month
Summary
ОСОБЕННОСТИ РЕГУЛЯЦИИ ЭРИТРОПОЭЗА У ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК 5Д СТАДИИ. Цель исследования: изучение особенностей цитокинового профиля у пациентов с хронической болезнью почек, получающих терапию программным гемодиализом. Материалы и методы: в исследование были включены 100 пациентов в возрасте 53,4±15,8 года с хронической болезнью почек 5Д стадии, получавших лечение программным гемодиализом. При этом наиболее тяжелая анемия ассоциирована с более низкой дозой эритропоэтина и препарата железа, применявшихся в течение последнего месяца. При сопоставлении уровня интерлейкина-3 и дозы эритропоэтина отмечается разнонаправленность этих показателей у пациентов с анемией различной степени тяжести. Установлена корреляция между уровнем интерлейкина-3 и флюктуацией дозы эритропоэтина в течение последнего года (r=0,54; р=0,01) у пациентов с легкой анемией, у больных с тяжелой анемией — с уровнем растворимых рецепторов трансферрина (r=0,84; р=0,04). Выводы: выявлена повышенная концентрация интерлейкина-3 и интерлейкина-6 у всех пациентов с хронической болезнью почек. Ключевые слова: хроническая болезнь почек, анемия, интерлейкин-3, интерлейкин-6, эритропоэтин
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
